Richard Nolan Townsend Sells 55,000 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 55,000 shares of the firm’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $5.69, for a total transaction of $312,950.00. Following the completion of the transaction, the chief executive officer directly owned 340,106 shares of the company’s stock, valued at $1,935,203.14. This represents a 13.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Richard Nolan Townsend also recently made the following trade(s):

• On Wednesday, February 18th, Richard Nolan Townsend sold 10,173 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $6.38, for a total transaction of $64,903.74.

Lexeo Therapeutics Price Performance

Shares of Lexeo Therapeutics stock opened at $6.44 on Thursday. The business has a fifty day simple moving average of $6.51 and a two-hundred day simple moving average of $7.97. Lexeo Therapeutics, Inc. has a 1 year low of $1.75 and a 1 year high of $10.99. The company has a market capitalization of $477.14 million, a price-to-earnings ratio of -2.94 and a beta of 1.99.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.05. As a group, equities analysts anticipate that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on LXEO shares. Raymond James Financial started coverage on Lexeo Therapeutics in a report on Wednesday, December 17th. They set a “strong-buy” rating and a $25.00 price target for the company. Chardan Capital reaffirmed a “buy” rating and set a $17.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, January 13th. HC Wainwright cut their price target on Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, January 13th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $20.00 price target on shares of Lexeo Therapeutics in a report on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $18.88.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. bought a new position in Lexeo Therapeutics during the 4th quarter worth $49,650,000. Paradigm Biocapital Advisors LP bought a new position in Lexeo Therapeutics during the 4th quarter worth $47,299,000. Vestal Point Capital LP increased its position in Lexeo Therapeutics by 37.7% during the 4th quarter. Vestal Point Capital LP now owns 4,475,000 shares of the company’s stock worth $44,437,000 after buying an additional 1,225,000 shares during the period. Frazier Life Sciences Management L.P. increased its position in Lexeo Therapeutics by 363.1% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,424,725 shares of the company’s stock worth $17,787,000 after buying an additional 3,469,210 shares during the period. Finally, Balyasny Asset Management L.P. bought a new position in Lexeo Therapeutics during the 2nd quarter worth $16,117,000. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.